XNK Therapeutics
Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She has over 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and worked as a biotechnology assessor at the Swedish Medical Products Agency. She has broad experience in regulatory affairs and the development of biologics and vaccines. Lena Degling Wikingsson is currently a non-executive Director of Simplexia and CEO of Dilafor AB.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
XNK Therapeutics
XNK Therapeutics is focused on realizing the potential in autologous NK cell therapies for cancer patients.